AuriNovo™ is designed to provide a treatment alternative to synthetic materials and rib cartilage grafts traditionally used to reconstruct the outer ear in patients with microtia. The US Food and Drug Administration (FDA) granted AuriNovo™ Orphan Drug and Rare Pediatric Disease Designation for treatment of microtia and has allowed 3DBio to initiate the first clinical trial using AuriNovo™. 3DBio Therapeutics’ first-of-its-kind investigational living tissue ear implant, AuriNovo™, is a patient-specific implant for surgical reconstruction of the outer ear in people born with microtia grades II-IV which affects ~1,500 births per year in the US. AuriNovo™ has not received FDA approval.

AuriNovo™ is created on-demand for patients using 3DBio’s pioneering approach which develops living tissue implants with structural and functional integrity using novel 3D-bioprinting and materials technologies.

### THE PATIENT JOURNEY

- **Patient’s own chondrocytes are obtained from a biopsy from the patient’s impacted ear**
- **Cells are expanded in a specialized cell culture system**
- **Patient’s cells are mixed with ColVivo™ collagen-based bio-ink**
- **Bio-ink is shaped, using the GMPrint™ 3D-bioprinter, into a living AuriNovo™ implant mirroring the size and shape of the patient’s opposite ear**
- **Patient’s AuriNovo™ is surrounded by a protective biodegradable Overshell to provide early structural support and implanted in the patient. The Overshell is resorbed by the body over time**
- **The implanted ear matures with time and develops the characteristics of a native ear, including flexibility, elasticity and a typical “look and feel”**
BREAKTHROUGH ADVANTAGES OF AURINOVO™
If AuriNovo™ is approved by the FDA for ear reconstruction, patients with microtia and their families could benefit from an unprecedented development in regenerative medicine. AuriNovo™ is designed:

• As a biocompatible implant that avoids implant rejection
• For reconstruction with outpatient surgical procedure
• For use in even young children
• To provide a reconstructed ear with natural flexibility and the look and feel of a natural ear expected to last a lifetime
• To avoid painful, complicated rib cartilage harvests—required for a current standard of care

ONGOING CLINICAL TRIAL
3DBio Therapeutics is currently conducting a Phase 1/2a clinical trial of AuriNovo™ for use in auricular reconstruction of microtic ears. The study will collect safety data, efficacy (aesthetic outcome) data, and evaluate technical, logistical, surgical and post-surgical care aspects of AuriNovo™ reconstruction. Subject will be followed for up to five years.

For more information on the trial, please see clinicaltrials.gov, (NCT04399239). To learn more about 3DBio Therapeutics, please visit 3DBioCorp.com.

Certain information set forth in this document may constitute “forward-looking statements” under applicable securities laws. There are a number of factors that could cause actual results or outcomes to differ materially from those addressed in such forward-looking statements. Thus forward-looking statements are provided only as an opportunity to understand management’s beliefs and opinions in respect of the company’s future prospects.